Novan to Host Live Audio Webcast of 2020 Annual Meeting of Stockholders
July 23 2020 - 08:05AM
Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today
announced that it will host a live audio webcast of the Company’s
2020 Annual Meeting of Stockholders ("ASM") on Tuesday, July 28,
2020 at 9:30 a.m. Eastern Time.
Considering the coronavirus (COVID-19) pandemic,
for the safety and health of Novan’s stockholders, employees and
the broader community, the Company has determined that its 2020
Annual Meeting will be held solely via the Internet. To be admitted
to the 2020 ASM webcast, stockholders need to visit
www.virtualshareholdermeeting.com/NOVN2020 and enter the control
number included on the proxy form or voting instruction form, as
applicable. During the virtual annual meeting, stockholders of
record as of June 11, 2020 will be able to vote their shares
electronically and will be able to ask questions via the web
portal, as time permits.
Guests may listen to the 2020 ASM by visiting
www.virtualshareholdermeeting.com/NOVN2020 and completing the guest
login section of the web portal. If you are not a stockholder of
record, you may still access and listen to the meeting, however,
guests will be unable to submit questions during the webcast.
Online check-in will begin 15 minutes prior, at
9:15 a.m. ET. The ASM will begin promptly at 9:30 a.m. ET on July
28, 2020.
About Novan
Novan, Inc. is a clinical development-stage
biotechnology company focused on leveraging nitric oxide’s
naturally occurring anti-microbial and immunomodulatory mechanisms
of action to treat a range of diseases with significant unmet
needs. We believe that our ability to deploy nitric oxide in a
solid form, on demand and in localized formulations allows us the
potential to improve patient outcomes in a variety of dermatology,
women’s health and gastrointestinal diseases.
Forward-Looking Statements
This press release contains forward-looking
statements including, but not limited to, statements related to
pharmaceutical development of nitric oxide-releasing product
candidates and our intention to advance development of certain
product candidates. Forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from our expectations, including, but not
limited to, risks and uncertainties in the clinical development
process, including, among others, length, expense, ability to
enroll patients, reliance on third parties, potential for delays
and that results of earlier research and preclinical or clinical
trials may not be predictive of results, conclusions or
interpretations of later research activities or additional trials;
risks related to the regulatory approval process, which is lengthy,
time-consuming and inherently unpredictable, including the risk
that our product candidates may not be approved or that additional
studies may be required for approval or other delays may occur and
that we may not obtain funding sufficient to complete the
regulatory or development process; our ability to obtain additional
funding or enter into strategic or other business relationships
necessary or useful for the further development of our product
candidates; and other risks and uncertainties described in our
annual report filed with the SEC on Form 10-K for the twelve months
ended December 31, 2019, and in our subsequent filings with the
SEC. These forward-looking statements speak only as of the date of
this press release, and Novan disclaims any intent or obligation to
update these forward-looking statements to reflect events or
circumstances after the date of such statements, except as may be
required by law.
INVESTOR AND MEDIA CONTACT:
Jenene Thomas JTC Team,
LLC833-475-8247NOVN@jtcir.com
Novan (NASDAQ:NOVN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novan (NASDAQ:NOVN)
Historical Stock Chart
From Mar 2023 to Mar 2024